Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Klinikum / Johannes Gutenberg-Universität Mainz
Stieglitz, Verena; Buggenhagen, Holger; Strelow, Kai-Uwe et al.
Action competence in obstetric emergencies-can this be achieved via e-learning? Interprofessional blended learning module on diagnostics and emergency treatment of shoulder dystociaBMC MEDICAL EDUCATION. Bd. 23. H. 1. 2023
Schmidt, Marcus; Nitz, Ulrike; Reimer, Toralf et al.
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trialEUROPEAN JOURNAL OF CANCER. Bd. 194. 2023
Thomssen, Christoph; Vetter, Martina; Kantelhardt, Eva J. J. et al.
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology GroupCANCERS. Bd. 15. H. 5. 2023
Park-Simon, Tjoung-Won; Mueller, Volkmar; Jackisch, Christian et al.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer (EBC): Update 2023BREAST CARE. Bd. 18. H. 4. 2023 S. 288-304
Thill, Marc; Kolberg-Liedtke, Cornelia; Albert, Ute-Susann et al.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023BREAST CARE. Bd. 18. H. 4. 2023 S. 305-314
Heitz, Florian; Marth, Christian; Henry, Stephanie et al.
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trialINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2023
Czogalla, Bastian; Trillsch, Fabian; Mahner, Sven et al.
Anastomotic leakage following bowel resection in radical cytoreductive surgery for ovarian cancer: A subgroup analysis of the prospective AGO-OVAR.OP3/LIONJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Decker, Thomas; Luedtke-Heckenkamp, Kerstin; Melnichuk, Luidmila et al.
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)BREAST. Bd. 72. 2023
Bartlett, John M. S.; Xu, Keying; Wong, Jenna et al.
Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Theis, S; Hasenburg, A; Almstedt, K
Beschwerden helfen?Gynäkologische Praxis. Bd. 50. H. 1. 2023 S. 1-8